8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549


                                    FORM 8-K


                             CURRENT REPORT PURSUANT
                          TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


     Date of report (Date of earliest event reported) March 29, 2007
                                                     ---------------------------

                           Interleukin Genetics, Inc.
- --------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)

                                    Delaware
- --------------------------------------------------------------------------------
                 (State or Other Jurisdiction of Incorporation)

          000-23413                                  94-3123681
- --------------------------------------------------------------------------------
   (Commission File Number)               (IRS Employer Identification No.)


     135 Beaver Street Waltham, MA                                  02452
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices)                          (Zip Code)

                                 (781) 398-0700
- --------------------------------------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)


- --------------------------------------------------------------------------------
          (Former Name or Former Address, if Changed Since Last Report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     |_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

     |_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

     |_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

     |_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))





Item 1.01 Entry into a Definitive Material Agreement.

On March 29, 2007, Interleukin Genetics, Inc. has entered into a new
research agreement with Access Business Group International LLC (ABG), a
subsidiary of Alticor Inc. The research agreement encompasses the development of
genetic tests to guide consumers' selection of appropriate skin care products;
the further development of tests for weight management and the risk of
osteoporosis, as well as the development of other tests. Under the terms of the
agreement, Interleukin is eligible to receive up to $2.3 million in additional
research funding during 2007.

A copy of the press release is attached hereto as Exhibit 99.1, and is
incorporated in this Item 1.01 by reference.

Item 9.01 Financial Statements and Exhibits.
(c) Exhibits.

Exhibit No.        Description
- -----------        -----------
   99.1            Press Release dated March 30, 2007.









                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                              Interleukin Genetics, Inc.
                                              --------------------------
                                              (Registrant)



Date: March 30, 2007                          /s/ TIMOTHY J. RICHERSON
                                              --------------------------------
                                              Timothy J. Richerson
                                              Chief Executive Officer
                                              (Signature)

EX-99.1

                                                                    EXHIBIT 99.1



  Interleukin Genetics Expands Research Collaboration with Alticor

    WALTHAM, Mass.--(BUSINESS WIRE)--March 30, 2007--Interleukin
Genetics, Inc. (AMEX: ILI) reported today that it has entered into a
new research agreement with Access Business Group International LLC
(ABG), a subsidiary of Alticor Inc. The research agreement encompasses
the development of genetic tests to guide consumers' selection of
appropriate skin care products; the further development of tests for
weight management and the risk of osteoporosis, as well as the
development of other tests. Under the terms of the agreement,
Interleukin is eligible to receive up to $2.3 million in additional
research funding during 2007.

    "Interleukin shares Alticor's vision of helping people live better
lives. We are pleased to increase the scope of our collaboration with
Alticor for the research and development of these personalized
wellness products in the effort to realize our shared vision," said
Tim Richerson, Chief Executive Officer of Interleukin Genetics.

    Previous research agreements between Interleukin Genetics and
Alticor led to the commercial launch in March 2006 of three
products--a proprietary genetic test for risk of early heart disease,
a novel and proprietary nutritional supplement beneficial for those
who test positive for that genetic risk factor, and a general
nutrition test panel.

    About Interleukin Genetics

    Interleukin Genetics, Inc. is focused on developing, acquiring,
and commercializing personalized health products that can help
individuals improve and maintain their health through preventive
measures. It uses functional genomics to help in the development of
risk assessment tests based on the genetic variations in people. The
Company also develops and markets nutritional and OTCeutical(R)
products. Interleukin has commercialized genetic tests for periodontal
disease risk assessment, cardiovascular risk assessment, and general
nutrition assessment. In addition, through its Alan James Group
subsidiary which it acquired in August 2006, Interleukin sells its
nutritional product brands, including Ginkoba(R), Ginsana(R), and
Venastat(R) through the nation's largest food, drug and mass
retailers. The Company's current development programs focus on
osteoporosis and weight management genetic risk assessment tests, as
well as its new proprietary OTCeuticals for distribution through Alan
James Group. The Company expects that these programs will also lead to
the personalized selection of nutritional products, and provide
consumers and healthcare professionals with better preventive product
alternatives. For more information about Interleukin and its ongoing
programs, please visit http://www.ilgenetics.com.

    Certain statements contained herein are "forward-looking"
statements including statements regarding our ability to develop
diagnostic, personalized nutritional and therapeutic products to
prevent or treat diseases of inflammation and other genetic
variations, our ability to screen nutritional compounds for their
effects on inflammatory responses and other genetic variations, given
specific genetic patterns, our ability to make progress in advancing
our core technologies, and our expectations regarding fiscal year 2006
revenues and gross profit margins of our nutritional supplement
products. Because such statements include risks and uncertainties,
actual results may differ materially from those expressed or implied
by such forward-looking statements. Factors that could cause actual
results to differ materially from those expressed or implied by such
forward-looking statements include, but are not limited to, the risk
of market acceptance of our products, the risk of technology and
product obsolescence, delays in product development, the performance
of our commercial partners, the availability of adequate capital, the
actions of our competitors and other competitive risks, our ability to
integrate acquired businesses, our ability to maintain relationships
with our important customers, and those risks and uncertainties
described in our annual report on Form 10-K for the year ended
December 31, 2005 filed with the Securities and Exchange Commission,
our quarterly reports on Form 10-Q and other filings made by us with
the Securities and Exchange Commission. We disclaim any obligation or
intention to update these forward-looking statements.

    CONTACT: For Interleukin Genetics:
             Paul Voegelin, 781-398-0700